Why is COMPUS Assessing Proton Pump Inhibitors (PPIs)?
COMPUS employed a unique and comprehensive process to examine the available evidence and ultimately generate best practice recommendations on the prescribing and use of PPI’s. Researchers at COMPUS with input from stakeholders: • Collected clinical practice guidelines (CPGs) and consensus documents (CDs) that met specific criteria on the use of PPIs for indications approved in Canada. • Extracted recommendations on PPIs, and grouped recommendations addressing the same clinical question into a synthesized statement. • Evaluated all relevant cited references for each grouping. • Identified relevant new evidence, from systematic reviews (SRs) and randomized controlled trials (RCTs) not yet incorporated in CPGs. • Identified and evaluated relevant Canadian economic studies. The key results of the consultation document: Summary of Findings on the Prescribing and Use of Proton Pump Inhibitors (COMPUS Interim Report) include: a) synopses of existing recommendations on the prescribing and use
